Respiratory Tract Infections in the USA

Questions: Discounts, Updates etc.

Price: $15,200.00

Publication Date: 2006-11-27

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

In the US, approximately 88 million people are diagnosed with a respiratory tract infection in an average year. Of these, a total of 66 million patients suffer from one of the three major diagnoses: acute bacterial sinusitis (ABS), acute exacerbation of chronic bronchitis (AECB) and community-acquired pneumonia (CAP).


Scope

  • Diagnosis patterns of the three conditions: ABS, AECB and CAP, based on a survey of 90 physicians across the US
  • Analysis of treatment regimens and preferences for ABS, AECB and CAP, according to Datamonitor's primary research data
  • Ranking of the greatest areas of unmet need for diagnostics and therapeutics within the RTI market
  • Evaluation of the reasons underlying prescription choices; discussion of the differences between diagnoses


    • Report Highlights
    According to Datamonitor research, 83-97% of patients diagnosed with RTIs receive antibiotic therapy regardless whether a bacterial pathogen could be identified or not. While beta lactams are preferred for ABS, newer macrolides and fluoroquinolones are routinely chosen to treat AECB and CAP.

    The lack of quick and reliable laboratory tests to identify the underlying pathogen results in 68-80% of treatments to be initiated empirically. About 16% of patients across the three conditions fail first-line treatment and move on to second line, mostly due to a lack of coverage for and drug resistance of the causative organisms.

    While physicians appear evenly divided between branded and generic drugs when prescribing for initially relatively benign conditions such as ABS and AECB, they strongly prefer newer, more expensive drugs both for more serious conditions such as CAP and when experiencing treatment failure of their initial drug choice.


    Reasons to Purchase

  • Identify the key factors that influence prescribing patterns for US RTI pharmacotherapy
  • Examine the remaining and emerging unmet needs in the US RTI market and identify opportunities for new product development
  • Enhance your commercial positioning through an improved understanding of the US RTI market dynamics

    • Table of Contents

    Other users found this report page using the following search terms: rsv Respiratory Syncytial Virus sinusitis bronchitis pneumonia treatment tract respiratory infections guidelines ats nosocomial datamonitor summary acquired

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.